Trimet-MR Tablet 35 mg contains Trimetazidine Dihydrochloride 35 mg in a modified-release (MR) formulation, designed for the long-term management of chronic stable angina. Trimetazidine is a metabolic antianginal agent that optimizes cardiac energy metabolism, enabling the heart to produce more energy efficiently, even under conditions of reduced oxygen supply.

The modified-release formulation ensures once-daily dosing, providing steady therapeutic levels throughout the day. Trimet-MR helps reduce the frequency and severity of angina attacks, improve exercise tolerance, and support overall cardiac function, making it an effective option for patients with coronary artery disease. Unlike traditional antianginal drugs, Trimet-MR works at the cellular level without significantly affecting heart rate or blood pressure.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Trimetazidine Dihydrochloride 35 mg (Modified-Release)

Mechanism of Action

Trimet-MR enhances cardiac efficiency through a targeted metabolic mechanism:

1. Metabolic modulation – Shifts myocardial energy production from fatty acid oxidation to glucose oxidation, generating more energy per unit of oxygen.

2. Cellular protection – Reduces the accumulation of toxic metabolites during ischemia, protecting cardiac cells from oxidative damage.

3. Improved tolerance to ischemia – Helps the heart function efficiently under low oxygen conditions, such as during physical exertion or stress.

4. Symptom reduction – By enhancing energy production in heart cells, Trimet-MR reduces the frequency and intensity of angina attacks without altering heart rate or blood pressure.

These effects contribute to improved cardiac performance and better quality of life for patients with chronic stable angina.

Indications

Trimet-MR Tablet 35 mg is indicated for:

• Chronic stable angina pectoris – to reduce angina episodes and their severity

• Adjunct therapy – in patients who require additional support beyond standard antianginal medications

• Prevention of ischemic episodes – helping patients tolerate physical activity without angina

• Cardioprotective support – particularly in patients with coronary artery disease or impaired cardiac oxygen supply

It is intended for long-term management and should be used under the supervision of a healthcare professional.

Dosage and Administration

• Recommended dose: 1 tablet (35 mg) once daily, preferably in the morning with or after meals.

• Swallow the tablet whole; do not crush, chew, or break, as this may interfere with the modified-release mechanism.

• Regular follow-up with a physician is advised to monitor treatment response and adjust therapy if necessary.

Benefits

• Provides effective reduction in frequency and severity of angina attacks

• Enhances exercise tolerance and daily physical activity

• Protects heart cells from ischemic damage and oxidative stress

• Convenient once-daily dosing improves adherence

• Minimal impact on heart rate and blood pressure, making it well-tolerated for long-term use

Precautions

• Use with caution in patients with severe renal impairment.

• Avoid in patients with Parkinson’s disease, movement disorders, or hypersensitivity to Trimetazidine.

• Do not abruptly discontinue therapy without medical advice.

• Inform your physician of all concomitant medications, especially antianginal or antihypertensive drugs.

• Pregnancy and breastfeeding require consultation with a healthcare professional before use.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects may include:

• Mild gastrointestinal discomfort, nausea, or headache

• Dizziness or fatigue

• Rare movement disorders such as tremors or Parkinsonian symptoms with long-term use

Serious adverse effects are uncommon but require immediate medical attention.

Storage

• Store below 30°C in a cool, dry place

• Protect from light and moisture

• Keep the container or blister pack tightly closed

• Keep out of reach of children

Trimet-MR Tablet 35 mg is a reliable modified-release antianginal therapy that improves cardiac efficiency, reduces angina symptoms, and enhances quality of life in patients with chronic stable angina under proper medical supervision.